Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course

International Journal of Cancer

Volumn 132, Issue 4, 2012, Pages 807-812

  Perner, Sven ^a   Rupp, Niels J ^b   Braun, Martin ^a   Rubin, Mark A ^c   Moch, Holger ^b   Dietel, Manfred ^d   Wernert, Nicolas ^a   Jung, Klaus ^d,e   Stephan, Carsten ^d   Kristiansen, Glen ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Berlin Institute of Urologic Research   (Germany)

Author keywords

ERG; gene rearrangement; prognostic biomarker; prostate cancer; SLC45A3; SLC45A3 protein; TMPRSS2

Indexed keywords

ONCOPROTEIN; PROSTEIN PROTEIN; PROTEIN TMPRSS2; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BENIGN TUMOR; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ERG GENE; FOLLOW UP; GENE; GENE FUSION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTEIN GENE; PROTEIN DEPLETION; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE MICROARRAY; TMPRSS2 GENE;

DOWN-REGULATION; GENE FUSION; GENE REARRANGEMENT; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS;

EID: 84871376542     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27733     Document Type: Article

References (15)

1. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8. (Pubitemid 41528150)
2. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008; 68: 7629-37.
3. Esgueva R, Perner S, Scheble V, et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol 2010; 23: 539-46.
4. Pflueger D, Rickman DS, Sboner A, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009; 11: 804-11.
5. Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 2010; 23: 1061-7.
6. Braun M, Goltz D, Shaikhibrahim Z, et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer-a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis 2012; 15: 165-9.
7. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13: 228-37.
8. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12: 590-8.
9. Lein M, Stibane I, Mansour R, et al. Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charite Hospital Berlin, Campus Mitte. Eur Urol 2006; 50: 1278-82; discussion 83-4.
10. Kristiansen G, Fritzsche FR, Wassermann K, et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer 2008; 99: 939-48.
11. Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011; 17: 5878-88.
12. Yaskiv O, Zhang X, Simmerman K, et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol 2011; 35: 1062-8.
13. van Leenders GJ, Boormans JL, Vissers CJ, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 2011; 24: 1128-38.
14. Xu J, Kalos M, Stolk JA, et al. Identification and characterization of prostein, a novel prostate-specific protein. Cancer Res 2001; 61: 1563-8. (Pubitemid 34292588)
15. Yin M, Dhir R, Parwani AV,. Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. Diagn Pathol 2007; 2: 41.